Ligand Pharmaceuticals | LGND - Operating Expenses


Ligand Pharmaceuticals reported $94.5M in Operating Expenses for its fiscal quarter ending in September of 2026.





Operating Expenses Change Date
Agenus USD -199.08M 22.15M Jun/2026
Amgen USD 11.69B 6.9B Jun/2026
Anika Therapeutics USD 137.28M 3.38M Jun/2026
Arrowhead Research USD 245.35M 30.35M Jun/2026
Baxter International USD 6.5B 3.82B Sep/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Eli Lilly USD 10.52B 496M Jun/2026
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
Enviri Corporation USD 233.18M 357.11M Mar/2026
Gilead Sciences USD 13.04B 9.09B Sep/2026
GlaxoSmithKline GBP 6.03B 227M Sep/2026
Glaxosmithkline GBP 5.34B 3.83B Mar/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Insmed USD 606.26M 79.46M Sep/2026
Intrexon USD 61.56M 26.1M Jun/2024
Ionis Pharmaceuticals USD 370.24M 6.24M Jun/2026
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026
Ligand Pharmaceuticals USD 94.5M 39.4M Sep/2026
MacroGenics USD 42.87M 21.68M Jun/2026
Merck USD 10.75B 5.02B Sep/2026
Pacira USD 180.54M 7.79M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Veracyte USD 126.36M 6.37M Jun/2026